Valuation: NOVARTIS

Market Cap 27TCr 24TCr 22TCr 20TCr 38TCr 25,68100Cr 38TCr 2,67800Cr 1,04200Cr 13,10700Cr 1,00100Cr 98TCr 42,13100Cr P/E 2026 *
19.8x
P/E 2027 * 16.6x
Enterprise Value 30TCr 27TCr 25TCr 23TCr 42TCr 28,70500Cr 43TCr 2,99300Cr 1,16500Cr 14,65100Cr 1,11900Cr 1,09500Cr 47,09200Cr EV / Sales 2026 *
5.17x
EV / Sales 2027 * 4.8x
Free-Float
91.66%
Yield 2026 *
3.09%
Yield 2027 * 3.23%
Manager TitleAgeSince
Chief Executive Officer 50 01/02/2018
Director of Finance/CFO - 16/03/2026
Compliance Officer 58 14/04/2025
Director TitleAgeSince
Director/Board Member 67 01/01/2015
Director/Board Member 69 01/01/2016
Director/Board Member 61 01/01/2016
Change 5-day change 1-year change 3-year change Capi.($)
+0.45%-2.98%+36.02%+112.28% 1,01900Cr
-1.03%-6.91%+34.55%+61.11% 62TCr
+0.13%-1.03%+14.48%+78.72% 46TCr
-3.21%-5.79%+57.75%+35.22% 36TCr
+0.93%-1.83%+20.98%+41.43% 33TCr
+0.12%-4.05%+10.09%+33.53% 27TCr
-0.89%-5.83%-7.56%+7.91% 24TCr
-0.27%-3.69%+36.92%+51.92% 22TCr
-0.52%-5.32%+26.89%+92.93% 18TCr
Average -0.59%-3.54%+25.57%+57.23% 41.08TCr
Weighted average by Cap. -0.44%-3.54%+28.67%+68.66%

Financials

2026 *2027 *
Net sales 5.77TCr 5.15TCr 4.8TCr 4.36TCr 8.22TCr 5,55700Cr 8.28TCr 58TCr 23TCr 2,83600Cr 22TCr 21TCr 9,11600Cr 6.14TCr 5.48TCr 5.1TCr 4.65TCr 8.75TCr 5,91500Cr 8.81TCr 62TCr 24TCr 3,01900Cr 23TCr 23TCr 9,70400Cr
Net income 1.43TCr 1.27TCr 1.18TCr 1.08TCr 2.03TCr 1,37300Cr 2.05TCr 14TCr 5.57TCr 70TCr 5.35TCr 5.24TCr 2,25300Cr 1.58TCr 1.41TCr 1.31TCr 1.19TCr 2.25TCr 1,52100Cr 2.27TCr 16TCr 6.17TCr 78TCr 5.93TCr 5.8TCr 2,49600Cr
Net Debt 3.14TCr 2.8TCr 2.61TCr 2.38TCr 4.47TCr 3,02400Cr 4.51TCr 32TCr 12TCr 1,54400Cr 12TCr 12TCr 4,96100Cr 2.82TCr 2.52TCr 2.35TCr 2.13TCr 4.02TCr 2,71800Cr 4.05TCr 28TCr 11TCr 1,38700Cr 11TCr 10TCr 4,45900Cr
Logo NOVARTIS
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA